Enzo Biochem, Inc. (ENZ) |
|
2.25 0.04 (1.81%)
|
06-06 15:51 |
|
Open: |
2.22 |
Pre. Close: |
2.21 |
|
High:
|
2.27 |
Low:
|
2.2 |
|
Volume:
|
77,210 |
Market Cap:
|
112(M) |
|
|
|
Technical analysis |
as of: 2023-06-06 3:18:40 PM |
|
Short-term rate:
|
 |
| Stoxline posted a BUY today, same as yesterday. Upward movement continues. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 2.92 One year: 3.2 |
| Support: |
Support1: 2.13 Support2: 1.77 |
| Resistance: |
Resistance1: 2.5 Resistance2: 2.74 |
| Pivot: |
2.28  |
| Moving Average: |
MA(5): 2.21 MA(20): 2.34
MA(100): 1.91  MA(250): 2.05 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 26.9 %D(3): 17.2 |
| RSI: |
RSI(14): 43.4 |
| 52-week: |
High: 2.75 Low: 1 |
| Average Vol(K): |
3-Month: 896 (K) 10-Days: 86 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENZ ] has closed above bottom band by 35.8%. Bollinger Bands are 48.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.25 - 2.26 |
2.26 - 2.27 |
|
Low:
|
2.17 - 2.18 |
2.18 - 2.19 |
|
Close:
|
2.22 - 2.24 |
2.24 - 2.26 |
|
Company Description |
|
Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York. |
Headline News |
Tue, 30 May 2023
Enzo Biochem Faces Cybersecurity Breach and Data Exposure - Best Stocks
Tue, 30 May 2023
The Cost of Ransomware Attacks Direct and Indirect Expenses - Best Stocks
Mon, 22 May 2023
Enzo Biochem Moves Closer to Clinical Lab Asset Sale with ... - Best Stocks
Thu, 18 May 2023
Is Enzo Biochem (NYSE:ENZ) Using Debt Sensibly? - Simply Wall St
Mon, 08 May 2023
SHAREHOLDER ALERT: The M&A Class Action Firm Continues ... - Digital Journal
Mon, 24 Apr 2023
Enzo Biochem, Inc. Announces Date of Special Meeting of Shareholders - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
50 (M) |
| Shares Float |
31 (M) |
|
% Held by Insiders
|
21.7 (%) |
|
% Held by Institutions
|
40.8 (%) |
|
Shares Short
|
1,190 (K) |
|
Shares Short P.Month
|
1,120 (K) |
Stock Financials |
|
EPS
|
-0.74 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.67 |
|
Profit Margin (%)
|
-43.5 |
|
Operating Margin (%)
|
-46 |
|
Return on Assets (ttm)
|
-25.2 |
|
Return on Equity (ttm)
|
-72 |
|
Qtrly Rev. Growth
|
-52 |
|
Gross Profit (p.s.)
|
0.84 |
|
Sales Per Share
|
1.63 |
|
EBITDA (p.s.)
|
-0.7 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-25 (M) |
|
Levered Free Cash Flow
|
-17 (M) |
Stock Valuations |
|
PE Ratio
|
-3.09 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.35 |
|
Price to Sales
|
1.37 |
|
Price to Cash Flow
|
-4.51 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
